Get answers to your Inflammatory Bowel Disease questions.
The University of Maryland Inflammatory Bowel Disease Program provides excellence in both medical and surgical therapeutics. Our specialists have expertise in prescribing not only the core medications used to treat IBD, including antibiotics, aminosalicylates and steroids, but also using immunomodulators such as mercaptopurine, azathioprine, methotrexate and cyclosporine.
In addition, our specialists have a great deal of experience with the newer biologic therapies such as infliximab (Remicade), adalimumab (Humira), certolizumab (Cimzia) and natalizumab (Tysabri), and offer an on-site infusion center. Our gastroenterologists also have ongoing clinical trials of investigational agents not yet approved by the Food and Drug Administration. Our gastroenterology specialists offer both routine and advanced endoscopic procedures on-site. Our program has a comprehensive group of endoscopists with expertise in diagnostic and therapeutic biliary endoscopy, endoscopic rectal ultrasound, therapeutic endoscopy and capsule endoscopy.
We have access to a state-of-the-art radiology department who not only offer standard imaging, but also abdominal and pelvic MRI, virtual colonoscopy and advanced interventional radiology procedures.
Our IBD surgeons specialize in using the most advanced minimally invasive (laparoscopic) techniques to treat all types of gastrointestinal illnesses. There are many advantages to this approach, including quicker recovery, shorter hospital stays, decreased post-operative pain and a significantly reduced risk of infection. As national leaders in the field, we continue to develop and investigate new laparoscopic techniques. Although we perform surgeries minimally invasively whenever possible, we are also very experienced in performing traditional (open) surgery.
Most importantly, each treatment -- whether it is medical or surgical -- is tailored to meet the needs of each individual patient.